Between the voriconazole and placebo groups , there were no significant differences in the number of severe exacerbations ( 1.16 vs 1.41 per patient per year , respectively ; mean difference , 0.25 ; 95 % CI , 0.19-0 .31 ) , quality of life ( change in Asthma Quality of Life Questionnaire score , 0.68 vs 0.88 ; mean difference between groups , 0.2 ; 95 % CI , -0.05 to -0.11 ) , or any of our secondary outcome measures .